China NMPA approves Astellas Pharma’s Padcev in combination with Keytruda to treat advanced bladder cancer: Tokyo Thursday, January 9, 2025, 09:00 Hrs [IST] Astellas Pharma Inc.

The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...

The study, published yesterday in the prestigious Journal of Clinical Oncology, identifies NECTIN4 amplification as a promising genomic biomarker for predicting treatment response to enfortumab ...